MedPath

Restoration of periprosthetic bone loss by zoledronic acid in total hip arthroplasty with osteoporosis.

Not Applicable
Conditions
Osteoporotic patients treaed with Total hip arthroplasty
Registration Number
JPRN-UMIN000034736
Lead Sponsor
Osaka University Graduate School of Medicine, Orthopedic Medical Engineering
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

The criteria of osteoporosis were not fulfilled.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The changes of periprosthetic bone mineral density were compared and evaluated at two years.
Secondary Outcome Measures
NameTimeMethod
Bone mineral density, bone biomarker, Japanese orthopaedic asssciation hip scpre, WOMAC were compared between groups.
© Copyright 2025. All Rights Reserved by MedPath